T-E Meds
T-E Meds, Inc. founded in 2014, focuses on the research and development of a series of novel drugs based on our “T-E” technology platform. These new pharmaceuticals, containing targeting (T) and effector (E) moieties, are created by proprietary “Multi-Arm Linkers”. The drug-design platform can be employed for constructing ultra-long-acting peptide drugs, and antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) with monospecific and bispecific antibodies.
